title: Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
abstract: A live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines have been applied to 887 and 148 children with various underlying diseases at the vaccine clinic of Osaka University Hospital between 1975 and 1985, respectively. Clinical reactions after mumps vaccination occurred in only 7 children (0.8%) and those after MRM vaccination in 28 children (19%), but their underlying diseases were not deteriorated by either vaccination. Clinical follow up study revealed that 2 of the 430 children immunized with mumps vaccine had contracted the disease during 7 year period and 2 of the 123 children immunized with MRM vaccine had contracted clinical mumps or rubella during 3 year period. The seroconversion rates after mumps vaccination were 70% and 61% by the hemagglutination inhibition (HI) test and neutralization (NT) test, respectively, while 94% by the fluorescent antibody to membrane antigen (FAMA) test. Those after MRM vaccination were 87% for measles, 96% for rubella by the HI test and 89% for mumps by the FAMA test. Serological follow up study revealed that antibodies elicited by mumps vaccination were sustained without substantial decline for at least 7 years. These results suggest that a live attenuated mumps and MRM vaccines are safe and effective in children with various underlying diseases.
authors.forename: T
authors.initials: T
authors.lastname: Kanesaki
authors.forename: K
authors.initials: K
authors.lastname: Baba
authors.forename: N
authors.initials: N
authors.lastname: Tsuda
authors.forename: H
authors.initials: H
authors.lastname: Yabuuchi
authors.forename: K
authors.initials: K
authors.lastname: Yamanishi
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis*; D002648:Child; D004338:Drug Combinations / Q000009:adverse effects / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine; D009107:Mumps / Q000150:complications / Q000517:prevention & control*; D009108:Mumps Vaccine / Q000009:adverse effects / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology*; D009500:Neutralization Tests; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated